PDCD1 and melanoma: When SK1 was silenced, PGEs was significantly reduced, leading to a significant reduction in the production of PGE2 (Prostaglandin E2 synthase), and enhancing the therapeutic response of melanoma to PD‐1/PD‐L1 monoclonal antibody.247